Skip to content

Effect of oral flora on neoadjuvant immunochemotherapy for locally advanced resectable esophageal cancer

Effect of oral flora on neoadjuvant immunochemotherapy for locally advanced resectable esophageal cancer

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500097932
Enrollment
Unknown
Registered
2025-02-27
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer

Interventions

Treatment Group:Pretreatment tooth cleaning + neoadjuvant immunochemotherapy

Sponsors

Department of Thoracic Surgery, West China Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Subjects must meet all of the following inclusion criteria before being enrolled in this study. (1) At the time of signing the informed consent, they were older than 18 years old (including 18 years old) and younger than 75 years old (including 75 years old), regardless of gender; (2) Locally advanced resectable esophageal cancer diagnosed clinically; (3) Plan to receive neoadjuvant chemoimmunotherapy and have the intention of surgical resection; (4) It was agreed to perform tooth cleaning intervention before neoadjuvant chemoimmunotherapy.

Exclusion criteria

Exclusion criteria: Subjects who meet any of the following criteria cannot be enrolled in this study. (1) Patients with esophageal cancer who had a previous history of chemoradiotherapy, immunotherapy or surgical treatment; (2) There are serious oral diseases, such as active periodontal disease, oral infection, etc., which are not suitable for dental cleaning intervention; (3) There are serious systemic diseases, such as cardiovascular disease, renal dysfunction, liver dysfunction, etc., which affect the reliability of the research results; (4) Other circumstances in which the investigator believes that the subject should not participate in this study

Design outcomes

Primary

MeasureTime frame
Pathological complete response rate;R0 resection rate;

Secondary

MeasureTime frame
Composition of oral flora;

Countries

China

Contacts

Public ContactYong Yuan

Department of Thoracic Surgery and Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu 610041, China.

yongyuan@scu.edu.cn+86 189 8060 6739

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026